GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SinoMab BioScience Ltd (HKSE:03681) » Definitions » Volatility

SinoMab BioScience (HKSE:03681) Volatility : 55.77% (As of Jun. 05, 2024)


View and export this data going back to 2019. Start your Free Trial

What is SinoMab BioScience Volatility?

Volatility is a statistical measure of the dispersion of returns for a given security or market index, it shows how the price swings around its mean. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year. In most cases, the higher the volatility, the riskier the security.

As of today (2024-06-05), SinoMab BioScience's Volatility is 55.77%.


Competitive Comparison of SinoMab BioScience's Volatility

For the Biotechnology subindustry, SinoMab BioScience's Volatility, along with its competitors' market caps and Volatility data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SinoMab BioScience's Volatility Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SinoMab BioScience's Volatility distribution charts can be found below:

* The bar in red indicates where SinoMab BioScience's Volatility falls into.



SinoMab BioScience  (HKSE:03681) Volatility Calculation

The annualized volatility is calculated as following:

σA=σM * 12
= 1/(n-1) ∑(Ri - R')^2 * 12

Where: σM is the monthly volatility, n is the number of months in the period, Ri is the security's historical monthly returns and R' is the arithmetic mean of monthly returns.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SinoMab BioScience  (HKSE:03681) Volatility Explanation

Volatility is a statistical measure of the dispersion of returns for a given security or market index. It’s often measured as standard deviation or variance of historical returns over a certain period. The volatility here is measured as the annualized standard deviation between monthly returns from the security over the past year.

Volatility reflects the uncertainty or risk of a security’s value. Generally speaking, a higher volatility suggests a higher risk, because it implies a wider fluctuation around average price. This means the price of the security can change dramatically in either direction within a short period. Conversely, a lower volatility means that the security's price is more steady, which suggests a lower risk.

Another measurement of relative volatility is Beta. Beta is a measure of systematic risk of a security or a portfolio in comparison to the market as a whole. Beta is usually compared to 1. A beta of greater than 1 indicates that the security's price will be more volatile than the market.


SinoMab BioScience Volatility Related Terms

Thank you for viewing the detailed overview of SinoMab BioScience's Volatility provided by GuruFocus.com. Please click on the following links to see related term pages.


SinoMab BioScience (HKSE:03681) Business Description

Traded in Other Exchanges
N/A
Address
No. 15 Science Park West Avenue, Units 303 and 305 to 307, Hong Kong Science Park, Pak Shek Kok, New Territories, Hong Kong, HKG
SinoMab BioScience Ltd is a biopharmaceutical company. The company is engaged in the research, development, manufacturing, and commercialization of therapeutics for the treatment of immunological diseases, primarily monoclonal antibody (mAb)-based biologics. Its flagship product, SM03 (Suciraslimab), is a potential global first-in target mAb for the treatment of rheumatoid arthritis (RA) and potentially for the treatment of other immunological diseases such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS) as well as non-Hodgkin's lymphoma (NHL), and other indications. The group derives revenue from Hong Kong.
Executives
Hainan Haiyao Co. Ltd. 2101 Beneficial owner
Liu Wenyi 2201 Interest of corporation controlled by you
Leung Shui On 2201 Interest of corporation controlled by you
Qiang Jing
West Biolake Holdings Limited 2101 Beneficial owner
Skytech Technology Limited 2101 Beneficial owner
China Citic Bank Co., Ltd., Haikou Branch 2106 Person having a security interest in shares
Xu Sijia 2101 Beneficial owner
Hai Kou Shi Nong Cun Xin Yong He Zuo Lian She 2106 Person having a security interest in shares
Apricot Oversea Holdings Limited 2101 Beneficial owner
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si 2101 Beneficial owner
Shang Hai Yue Yi Tou Zi Zhong Xin You Xian He Huo 2201 Interest of corporation controlled by you
Shang Hai Xing Ze Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Hai Nan Hai Yao Gu Fen You Xian Gong Si 2101 Beneficial owner

SinoMab BioScience (HKSE:03681) Headlines

No Headlines